New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows
June 20, 2024 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., June 20, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.’s (Nasdaq: COCP) novel, broad-spectrum antiviral CC-42344 inhibits activity in the highly pathogenic avian influenza A (H5N1)...
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
March 19, 2024 08:00 ET
|
Cocrystal Pharma, Inc.
Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial BOTHELL, Wash., March 19, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or...
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness
July 20, 2023 08:00 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, July 20, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Phase 2 PENINSULA (PrevEntioN of IllNesS DUe to InfLuenza A) trial evaluating VIR-2482...
Vir Biotechnology Announces First Patient Dosed in Groundbreaking Phase 2 Trial of VIR-2482 for Antibody Prophylaxis of Influenza A
October 18, 2022 08:00 ET
|
Vir Biotechnology, Inc.
– First clinical trial evaluating the role of a monoclonal antibody in preventing seasonal flu – – Announcement follows recent U.S. government award from the Biomedical Advanced Research and...
Cocrystal Pharma Reports CC-42344 Pharmacokinetic Data in Influenza A Once-Daily Dosing
July 14, 2022 08:00 ET
|
Cocrystal Pharma, Inc.
Single Ascending Dose Portion of Phase 1 Study Completed BOTHELL, Wash., July 14, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that...
Vir Biotechnology to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
September 08, 2021 16:05 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside...
Vir Biotechnology to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 16:05 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Howard Horn, chief financial officer, is scheduled to present at the H.C. Wainwright 23rd...
Cocrystal Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company, announces that management will...
Cocrystal Pharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update
August 09, 2019 08:05 ET
|
Cocrystal Pharma, Inc.
– Company continues to drive clinical and research programs forward to achieve multiple value-driving milestones– – Business development initiative underway with active discussions ongoing to secure...